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Abstract Melanin-concentrating hormone (MCH) is highly ex-
pressed in the brain and modulates feeding behavior. It is also
expressed in some peripheral tissues where its role remains un-
known. We have investigated MCH function in human and
mouse immune cells. RT-PCR analysis revealed a low expres-
sion of prepro-MCH and MCH receptor 1 (MCHR1) but not of
MCHR2 transcript in tissular and peripheral blood immune
cells. FACS and in vitro assay studies demonstrated that
MCHR1 receptor expression on most cell types can trigger,
in the presence of MCH, cAMP synthesis and calcium mobili-
zation in peripheral blood mononuclear cells (PBMCs). More-
over, MCH treatment decreases the CD3-stimulated PBMC
proliferation in vitro. Accordingly, our data indicate for the ¢rst
time that MCH and MCHR1 may exert immunomodulatory
functions. / 2002 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Melanin-concentrating hormone (MCH) is a cyclic peptide
originally isolated from the salmon pituitary gland [1] that
plays important roles in skin pigmentation or in some aspects
of the stress response in ¢sh. Later on, many studies have
demonstrated that this peptide is ubiquitous throughout the
vertebrate phylogeny [2]. In mammals, the highest MCH tran-
script level is observed in the brain, MCH expressing neurons
being largely restricted to the lateral hypothalamus and the
zona incerta whose ¢bers innervate a wide variety of brain
and medullar nuclei [3]. This neuronal system is then well
suited to coordinate goal-directed behaviors such as food in-
take, awakeness and sexual behavior. Many studies have now
con¢rmed its importance in the ¢eld of nutrition [4^7]. Never-
theless, only few experiments have been focused on MCH
production or on its e¡ects in peripheral tissues; thus, at
present, its role in these tissues remains largely unknown.
Only recently MCH was shown to stimulate insulin release
in CRI-G1 and RINm5F insulinoma cells lines, a model of
Langerhans islets cells [8], and to regulate leptin synthesis and
secretion in rat adipocytes [6]. Using RT-PCR, Hervieu and
Nahon detected prepro-MCH (ppMCH) messenger in the
stomach, testes, intestine and spleen of both the rat and the
mouse [9,10]. By in situ hybridization on rat spleen sections,
MCH mRNAs were revealed in scattered cells of unknown
phenotype [9]. In mouse spleen extracts however, signi¢cant
amounts of MCH immunoreactive material corresponding to
an intermediate cleavage form were detected but no immuno-
cytochemical experiments have been performed to localize it
at the cell level [11]. On another hand, it had been demon-
strated by RT-PCR that the mouse and human MCH recep-
tor 1 (m- and hMCHR1) are expressed, also at low levels, in
the spleen and thymus [12]. Moreover, by analysis of the 5P-
upstream region of the mMCHR1 gene we have revealed the
presence of many putative binding sites for MZF1 and Ikaros
transcription factors [13]. Finally, a gamma-interferon respon-
sive element has been found in the MCH gene [14]. These data
led us to examine if MCH may play a functional part in the
immune system.
2. Materials and methods
2.1. Cell lines and culture conditions
Chinese hamster ovary (CHO) cell line expressing the hMCHR1
receptor was kindly provided by E. Burgeon (Euroscreen, Brussels,
Belgium). Human peripheral blood mononuclear cell (PBMC) were
obtained from bu¡y coats of healthy donors (Transfusion Center,
Lie'ge, Belgium). C6 and SKN-BE cell lines were generous gifts
from B. Rogister (CNCM, University of Lie'ge, Lie'ge, Belgium).
Cells were kept in RPMI 1640 or DMEM (BioWhitaker, Verviers,
Belgium) supplemented with 10% fetal calf serum (BioWhitaker), 100
IU/ml penicillin/streptomycin (BioWhitaker). This study protocol was
approved by the Ethics Committee of the University Hospital of Lie'ge
2.2. Lymphocytes isolation
Tonsils from 1^8-year-old children were surgically removed and
placed in a cold physiological solution containing 0.4% BSA (Sigma,
St. Louis, MO, USA). Lymphocyte populations were prepared by
gently teasing the tonsils. For human PBMCs isolation, human blood
was diluted 1:1 in RPMI 1640 (BioWhitaker), and centrifuged on a
Ficoll (AP Biotech, Uppsala, Sweden) gradient for 25 min at 830Ug.
Interface cells were harvested and washed three times with PBS [15].
2.3. RNA isolation and RT-PCR
Total RNAs were extracted from human PBMC, human tonsils,
spleens and thymuses of C57BL6 mice using Instapure (Eurogentec,
Seraing, Belgium) according to the manufacturer’s protocol. 5 Wg of
total RNAs was reverse transcribed by MMLV (Invitrogen Life Tech-
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nologies, Carlsbad, CA, USA) with a random hexamer (AP Biotech)
for GAPDH and MCHR analysis or with a speci¢c oligonucleotide
hybridizing in the 3P-untranslated region for ppMCH analysis.
2 Wl of cDNA was ampli¢ed in a 100-Wl volume of ¢nal reaction
mix (2.5 U of Taq DNA polymerase (AP Biotech); 1.5 mM MgCl2 ;
200 WM dNTPs (AP Biotech)) with 50 pmol of speci¢c primers:
hppMCH forward 5P-GTTTCAAAGAACACAGGCTCC-3P (exons 1
and 2), reverse 5P-TATCAGACTTGCCAACAAGGTC-3P (exon 3);
hMCHR1 forward 5P-CCCGATAACCTCACTTCGG-3P (exon 1), re-
verse 5P-GACTATTGGCATCCATGGC-3P (exon 2); hMCHR2 for-
ward 5P-AACTGCCAGTGTGGTGGATACAG-3P (exon 2), reverse
5P-CTTGTTCTCCAACGTGTCAGTCG-3P (exon 4); mppMCH for-
ward 5P-GGTATCAGACTTGCCAACATGG-3P (exons 1 and 2), re-
verse 5P-AAGAATTCAAAGAACACAGGCTCC-3P (exon 3); mM-
CHR1 forward 5P-CCAGGATAATTTCACATTGGCG-3P (exon 1),
reverse 5P-CCCAAAGTCCAGACACCAT-3P (exon 2); GAPDH for-
ward 5P-ACCACAGTCCATGCCATCAC-3P ; reverse 5P-TCCAC-
CACCCTGTTGCTGTA-3P. PCR conditions were as follows: 1 min
at 95‡C followed by 40 cycles of 30 s at 95‡C, 30 s at 60‡C, 30 s at
72‡C, and a ¢nal extension of 10 min at 72‡C. 10-Wl aliquots of
ampli¢ed products were analyzed on agarose gels.
2.4. Phenotypic analysis
MCHR1 expression was carried out with a rabbit polyclonal anti-
body, raised against C-terminal part (kindly provided by G. Hervieu),
and revealed by a swine anti-rabbit FITC antibody (DAKO, Den-
mark, Glostrup). The double-staining phenotype was performed on
2U106 cells incubated with a anti-CD3 (PerCP), anti-CD14 (PE) or
anti-CD-19 (PerCP) antibody (B^D Bioscience, Erembodegem, Bel-
gium) during 30 min at 4‡C, washed with PBS, and treated with a
FACS1 permeabilizing solution (B^D Bioscience). After incubation
with the MCHR1 primary antibody for 1 h at room temperature, the
cells were washed in order to remove the excess of primary antibody.
The secondary antibody was then added to the cells for 30 min at
room temperature and the cells were washed and harvested with a
FACSCalibur (B^D Bioscience). The data were analyzed with the
CellQuest software.
2.5. Ca 2+ measurement
Ten million cells were incubated in 1 ml of HBSS without Ca2þ
containing 6 Wl of a 10% pluronic acid solution and 2 Wl of Fluo3/AM
2 mM (Molecular Probes, Leiden, The Netherlands) for 20 min at
20‡C. Four volumes of HBSS without Ca2þ were then added and
the incubation was continued for 40 min at 37‡C. Cells were washed
three times by HBSS without Ca2þ, resuspended in HBSS, with or
without Ca2þ and directly harvested with a FACSCalibur as described
above.
2.6. Cyclic AMP measurement
Two million PBMCs per well stimulated by puri¢ed anti-CD3 anti-
body (10 ng/ml) (B^D Biosciences), were cultured with or without 100
nM MCH (Bachem, Bubendorf, Switzerland). Following 24, 48 or
72 h of culture, the cells were pelleted and washed twice with PBS.
The cAMP was then extracted by sonication in ethanol 95%/HCl
0.01 N. The cellular suspensions were dried in a speed-Vac apparatus
and stored at 380‡C. The cAMP level was measured using the Enzy-
meImmunoAssay kit (AP Biotech) according to the manufacturer’s
protocol.
2.7. T-cell proliferation
PBMCs stimulated by puri¢ed anti-CD3 antibody (1 or 10 ng/ml)
were cultured at a density of 105 cells/well, with or without di¡erent
concentrations of MCH (1, 10, 100 and 1000 nM). During the last 4 h
of culture, the cells were incubated with 1 WCi of [3H]thymidine (6.7
Ci/mmol, AP Biotech). Following the culture (24, 48 or 72 h), cells
were harvested on ¢berglass ¢lters and isotope incorporation was
measured by liquid scintillation counting.
2.8. Statistical methods
For comparison of two groups, the non-parametric Mann^Whitney
test was used using Instat Mac software packages (Graph Pad Soft-
ware, San Diego, CA, USA).
Results of proliferation were expressed as meanQ standard devia-
tion. The relationship between [3H]thymidine incorporation levels and
MCH dose, culture time and anti-CD3 concentrations was analyzed
by means of the general linear mixed model (GLMM). Linear and
quadratic e¡ects for MCH dose were tested. Results were considered
to be signi¢cant at the 5% critical level (P6 0.05). Calculations were
carried out using SAS (version 6.12 for Windows).
3. Results
3.1. Expression of ppMCH and MCHRs mRNA in immune
cells
Some previous data showed an expression of ppMCH and
MCHR1 mRNA at least in the spleen [9] but no study had
ever demonstrated the presence of these transcripts in isolated
immune cells. Therefore, RT-PCR analysis was performed to
evaluate their expression in mouse splenocytes and thymo-
cytes. For ppMCH mRNA analysis, we have used primers
allowing to selectively amplify ‘authentic’ ppMCH but not
its variant or MGOP [17]. After electrophoresis, faint speci¢c
bands for ppMCH and MCHR1 mRNA were obtained in
mouse splenocytes and thymocytes (Fig. 1A) and the expected
sequences were con¢rmed by sequencing. The study was ex-
tended to human immune cells. The ppMCH and MCHR1
mRNA were detected in all tonsilar, PBMC and granulocytes
preparations. On the contrary, MCHR2 receptor mRNA was
never detected in the tonsilar and PBMC samples (Fig. 1B).
This con¢rms its more restricted tissue distribution [12]. Our
data indicate that immune cells express mRNA encoding
ppMCH and the MCHR1 receptor.
3.2. Expression of functional MCHR1 receptor
To verify that the MCHR1 receptor is e¡ectively translated
we have used a rabbit antibody raised against the C-terminal
part of the receptor, validated for immunocytochemistry stud-
ies [8,16]. It was ¢rst tested for FACS analysis. CHO cells
stably expressing the human receptor and C6 glioma cells,
not expressing it, were analyzed. According to the RT-PCR
results (not shown), a strong £uorescent signal was observed
in the CHO cells whereas no £uorescence was detected in the
C6 glioma cells. Additional control carried out with non-per-
meabilized PBMC was also negative (Fig. 2A). This demon-
strate that the antibody recognizes an intracellular epitope
only present in MCHR1 expressing cells and therefore dem-
onstrate a speci¢c immunoreactivity to MCHR1. The pheno-
typic analysis revealed an average of 95% MCHR1-positive
cells among the PBMC and 50% in the tonsilar cell popula-
tion. Using double labellings with anti-CD3 PerCP or anti-
CD19 PerCP antibodies, we measured that more than 98% of
the T-lymphocytes and more than 97% of the B-lymphocytes
expressed MCHR1. Within the monocyte population
(CD14+), we also observed a high percentage (s 97%) of
positive MCHR1 cells (Fig. 2B).
To assess the functional activity of the MCHR1 receptor,
we have analyzed the MCH e¡ect on the cAMP concentra-
tion. An inhibitory e¡ect on forskolin-stimulated cAMP ac-
cumulation was obtained similar to the results of previous
studies on CHO transfected cells [18]. We obtained equivalent
results with neuroblastoma SKN-BE cells (data not shown).
However, the addition of 100 nM and 1000 nM MCH during
1 day on activated PBMC produced a very signi¢cant incre-
ment in the total content of cAMP (P6 0.01) (Fig. 3A). After
48 or 72 h of culture, the values did not signi¢cantly di¡er
from the control values (Fig. 3B).
To extend the MCHR1 functional activity, we have mea-
sured the calcium response of PBMC after addition of MCH.
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Flow cytometric method by using the calcium probe £uo-3
was applied in the analysis of intracellular calcium mobiliza-
tion upon in vitro stimulation with 1 WM MCH (Fig. 3C). A
fast mobilization was observed following MCH addition
meaning a fast release of calcium from the endoplasmic retic-
ulum into the cytoplasm. Using calcium containing medium,
we found that intracellular calcium mobilization reached high-
er levels and stayed longer as expected for Ca2þ in£ux phe-
nomenon meaning a extracellular calcium entry in addition to
the calcium release from the endoplasmic reticulum into the
cytoplasm (Fig. 3C).
3.3. Inhibition of in vitro lymphocyte proliferation by MCH
To evaluate a possible modulation e¡ect of MCH on im-
mune cell functions, we tested its action on proliferation using
the [3H]thymidine incorporation method. Cultured human
PBMC were stimulated with two concentrations of a puri¢ed
anti-CD3 antibody (1 and 10 ng/ml) and treated with di¡erent
Fig. 1. RT-PCR analysis of ppMCH, MCHR1 and MCHR2 mRNA expression in mouse (A) and human (B) immune cells. In negative con-
trol, the MMLV reverse transcriptase was omitted. For hMCHR2, a brain mRNA sample was used as positive control
Fig. 2. Flow cytometry analysis of MCHR1 receptor. A: Validation of the anti-MCHR1 antibody for FACS. CHO cells stably expressing
MCHR1, C6 glioma cells and non-permeabilized (NP) PBMC stained with the rabbit anti-MCHR1 antibody (shaded area) as compared to
control incubated only with the secondary antibody (light area). B: Representative dot plot analysis of human PBMC double-stained with the
anti-MCHR1 antibody and with anti-CD3 (PerCP), or anti-CD14 (PE) or anti-CD19 (PerCP) antibodies.
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concentrations of MCH (0, 1, 10, 100 and 1000 nM) for 48
and 72 h (Fig. 4). By applying a GLMM to the [3H]thymidine
incorporation data, we found a signi¢cant linear (P6 0.0001)
and quadratic (P6 0.0001) e¡ect of MCH dose as well as a
signi¢cant e¡ect of culture time (P6 0.0001) (Table 1). The
[3H]thymidine incorporation levels were signi¢cantly higher
following 72 h than following 48 h of culture. The anti-CD3
concentration did not a¡ect [3H]thymidine incorporation lev-
els (P=0.11). As a result these data indicate that MCH re-
duces the human PBMC proliferative activity.
Fig. 3. E¡ect of MCH on cAMP concentrations (A, B) and calcium mobilization (C). A: Dose response of human PBMC incubated for 24 h
with 10 ng/ml anti-CD3 and with di¡erent concentrations of MCH. B: In£uence of incubation time on cAMP level of human PBMC cultured
in the presence of anti-CD3 10 ng/ml and with (shaded bars) or without (light bars) addition of 100 nM MCH. Data are expressed as a per-
centage of the cAMP produced and values are the meanQS.E.M. from eight or ten di¡erent samples performed in triplicate. C: Intracellular
calcium mobilization was induced in human PBMC following addition of 1 WM MCH in a physiological solution containing (left panel) or not
calcium (right panel).
Table 1
Results of the GLMM application to [3H]thymidine levels
E¡ect Regression coe⁄cient Standard error P value
Intercept 20 234 7426.8 ^
Dose 384.46 19.78 6 0.0001
Dose2 0.0820 0.0194 6 0.0001
Time 505.7 85.50 6 0.0001
Anti-CD3 3271.6 169.9 0.11
n=171 observations.
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4. Discussion
The involvement of MCH and its receptor(s) in the immune
system still remain unexplored. To our knowledge, we present
here the ¢rst study reporting data demonstrating that MCH
and its receptor MCHR1 can act as modulators of the im-
mune system. Previously, the ppMCH and MCHR1 tran-
scripts were observed in tissues like spleen or thymus but
not in speci¢c immune cells [9,10]. On base of RT-PCR anal-
ysis we showed the presence of the ppMCH and MCHR1
mRNA not only in mouse splenocytes and thymocytes but
also in human tonsilar and blood cells. The absence of
MCHR2 expression in human tonsils and PBMC is in agree-
ment with its restricted tissue distribution described in pre-
vious studies [13,19,20].
Our work shows also that immune cells express functional
MCHR1 receptors at their surface. By £ow cytometry, we
observed that a high percentage of the T- and B-lymphocytes
from PBMC or tonsil express MCHR1. To verify if the re-
ceptor is functionally coupled to G proteins, MCH e¡ect on
the cAMP levels and Ca2þ signalling pathways was analyzed.
The calcium mobilization was increased in PBMC following
addition of MCH. Interestingly, the MCH peptide stimulated
cAMP production in human PBMC whereas it decreased
cAMP levels in CHO-hMCHR1, SK-N-BE or melanoma
SK-MEL-37 cell lines [21]. Indeed, the concentration of
G proteins, receptor density, compartimentalization of signal
transduction machinery and accessibility of G proteins may
change according to the cell type, leading to di¡erent inter-
actions [22]. For example, MCH increases the forskolin-stimu-
lated insulin release when applied on CRI-GI and RINm5F
cell lines naturally producing MCHR1 mRNA, suggesting
that the peptide increases cAMP levels [8]. In accordance to
our results, MCHR1 appears functional in PBMC and prob-
ably coupled to a Gs protein. However, the observed e¡ect
could also be due to the presence of another, yet still unchar-
acterized, MCHR coupled mainly to Gs.
In vitro proliferation assay highlights a possible modulatory
function on lymphocyte by MCH. Indeed, the MCH peptide
signi¢cantly decreased CD3-stimulated PBMC proliferation.
This reduction of T-cell proliferation might be correlated
with an increase of cAMP production [23] ; indeed, the ob-
served inhibition of PBMC proliferation, following 48 and
72 h of culture is probably correlated with the cAMP level
increase observed following 24 h of culture. It would be of
interest to determine the T-cell subtypes sensitive to MCH
and the cytokines induced by this peptide. The phenotype of
immune cells able to secrete MCH containing peptide (i.e.
preMCH) or mature MCH peptide must be further analyzed
as well as the factors controlling this production.
In conclusion, in the current stage of our knowledge, this
study is the ¢rst to demonstrate the production of ppMCH
and functional expression of MCHR1 receptor by mouse and
human immune cells. An immunomodulatory role for MCH
and MCHR1 receptor can thus be proposed for both the
B- and T-cell populations.
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